Newsroom

First Subjects Enrolled in Clinical Study to Evaluate Safety and Efficacy of OMNI™ Surgical System for Multiple Micro-Invasive Glaucoma Surgery Procedures

MENLO PARK, Calif. – Sight Sciences today announced enrollment has begun in the Gemini clinical study, a Sight Sciences-sponsored, prospective, multi-center study to evaluate the safety and efficacy of the OMNI™...

read more +
Clinical Study Demonstrates Long Term IOP Reduction With The OMNI™ Surgical System Predicate Device (TRAB™360) In Micro-Invasive Glaucoma Surgery

A new, single center retrospective study of glaucoma surgery patients published in the January 2019 issue of Clinical Ophthalmology shows that ab-interno trabeculotomy using one of Sight Sciences’ OMNI™ Surgical...

read more +
Reay H. Brown, M.D., Joins Sight Sciences as Chief Medical Officer

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye treatment, today announced Reay H. Brown, M.D., has...

read more +
Sight Sciences Names Jesse Selnick Chief Financial Officer

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye treatment, today announced the appointment of Jesse Selnick...

read more +
Sight Sciences Expands Surgical Portfolio with FDA Clearance of the OMNI™ Surgical System

Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic device company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its OMNI™ Surgical System, a surgical tool dually indicated...

read more +
Sight Sciences Secures $10MM in Oversubscribed Series C Financing

Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company today announced it has closed an oversubscribed $10 million Series C round of growth financing and strengthened its leadership team with...

read more +
Sight Sciences Announces Expanding Management Team of Seasoned Medical Device Experts

Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced an expansion of its management team to support its recent regulatory milestones and commercial success. New hires include...

read more +
Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO™360 Versus SLT Glaucoma Trial

Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received full IDE approval from the FDA to initiate the world’s first clinical trial comparing...

read more +